By Hendra Lukman 
Every moment, the bone marrow orchestrates a ceaseless production line, generating millions of fresh blood and immune cells. This vital process, a testament to the body’s regenerative power, hinges on a delicate and dynamic equilibrium. Hematopoietic stem cells (HSCs), the foundational cells for all blood components, must maintain a finely tuned relationship with supportive stromal cells and a complex network of immune signaling molecules. This intricate dance ensures the steady supply of healthy cells essential for life.
However, this meticulously balanced system becomes increasingly vulnerable with the passage of time. The natural process of aging, coupled with chronic inflammatory conditions or the accumulation of somatic mutations within the stem cell population, can erode the crucial communication channels between these cellular players. This disruption can lead to a decline in normal stem cell renewal, creating an environment where mutated HSCs, carrying subtle but significant genetic alterations, can proliferate and expand without immediate detection. This phenomenon, known as clonal hematopoiesis of indeterminate potential (CHIP), is far from rare, affecting an estimated 10% to 20% of adults over the age of 60 and a striking nearly 30% of those over 80. While individuals with CHIP typically remain asymptomatic, the condition represents a significant harbinger of future health challenges. It elevates the risk of developing blood cancers by a tenfold margin and doubles the likelihood of experiencing cardiovascular disease and premature mortality. A closely related and more severe disorder, myelodysplastic syndrome (MDS), also involves clonal HSCs but is characterized by inefficient blood cell production, ultimately leading to the gradual failure of the bone marrow. MDS impacts up to 20 in every 100,000 adults over 70, and a concerning approximately 30% of these cases progress to acute myeloid leukemia (AML), an aggressive and often fatal malignancy.
Despite the recognized seriousness of these blood disorders, the precise contribution of the bone marrow’s intricate microenvironment – the specialized ecosystem surrounding the HSCs – to their development has remained an area of significant scientific inquiry, leaving a critical gap in our understanding of disease initiation.
Mapping Hidden Changes in the Bone Marrow Microenvironment
To illuminate the mechanisms by which mutated HSC clones gain dominance within the bone marrow, an international consortium of researchers, spearheaded by Judith Zaugg from the European Molecular Biology Laboratory (EMBL) and the University of Basel, and Borhane Guezguez from the University Medical Center Mainz (UMC Mainz), embarked on an ambitious undertaking. Their objective was to conduct an extensive molecular and spatial analysis of human bone marrow, integrating multiple cutting-edge technologies. The study drew upon samples from the established BoHemE cohort, a vital resource for bone marrow research, in collaboration with Uwe Platzbecker at the National Center for Tumor Diseases (NCT) Dresden.
The research team employed a sophisticated arsenal of techniques, including single-cell RNA sequencing, advanced biopsy imaging, proteomics, and meticulously designed co-culture models. This multi-pronged approach allowed them to construct a highly detailed molecular and spatial map of the bone marrow microenvironment. They meticulously analyzed samples from healthy donors, crucially including those identified as having CHIP, alongside samples from patients diagnosed with MDS. Their comprehensive analysis yielded a startling revelation: a significant and unexpected cellular shift occurs within the bone marrow long before any clinical manifestations of disease become apparent. The researchers identified a gradual replacement of the conventional mesenchymal stromal cells (MSCs), which are essential for supporting stem cell function, by a distinct population of inflammatory stromal cells.
"I was surprised to observe such pronounced remodeling of the bone marrow microenvironment already in individuals with CHIP, although the underlying cause-and-effect relationships remain unclear," stated Zaugg, a co-senior author on the study, EMBL Group Leader, and Professor at the University of Basel. This observation underscores the fact that the detrimental changes can begin at a very early stage of the disease process, even when the individual is seemingly healthy.
The Rise of Inflammatory Stromal Cells and Their Impact
Unlike their healthy counterparts, these newly identified inflammatory MSCs (iMSCs) exhibit a remarkable capacity to produce substantial quantities of interferon-induced cytokines and chemokines. These potent signaling molecules act as attractants and activators for interferon-responsive T cells, a critical component of the immune system. The presence and activation of these T cells, in turn, amplify the inflammatory activity within the bone marrow. This creates a self-perpetuating, or feed-forward, loop that sustains chronic inflammation. This persistent inflammatory state disrupts the normal, healthy process of blood formation and contributes to detrimental vascular changes within the marrow. The cumulative effect is a microenvironment that is no longer conducive to the healthy regeneration of blood cells.
Identifying What Drives Bone Marrow Inflammation
A crucial aspect of the research focused on discerning the root cause of this escalating inflammation. Interestingly, the study’s findings did not support the hypothesis that mutated hematopoietic cells in MDS directly trigger this inflammatory cascade. To rigorously investigate this, the researchers developed a sophisticated computational method, SpliceUp, spearheaded by co-lead author and EMBL alumnus Maksim Kholmatov in collaboration with Pedro Moura and Eva Hellström-Lindberg from the Karolinska Institute. SpliceUp excels at identifying mutated cells within single-cell datasets by detecting aberrant RNA-splicing patterns, a hallmark of genetic alterations. Utilizing this tool, they were able to effectively separate mutated from non-mutated cells within their samples. Their analysis revealed that in MDS, the inflammatory network within the microenvironment emerges as the dominant force, effectively displacing and replacing much of the bone marrow’s normal regenerative architecture.
"Another striking observation was that MDS stem cells couldn’t trigger stromal cells to produce CXCL12, an important signal that triggers blood cells to settle in the bone marrow. This failure may help explain why the bone marrow stops working properly," commented Karin Prummel, a co-lead author and EMBL postdoc. CXCL12 plays a critical role in anchoring blood cells within the bone marrow niche, and its absence can lead to impaired homing and retention of newly formed blood cells.
"It was quite surprising to see the lack of a direct inflammatory effect that we could attribute to the mutant cells," added Maksim Kholmatov, co-lead author and EMBL alumnus. "However, when viewed in the context of changes in the T cell and stromal compartments, it underlines the importance of the bone marrow microenvironment in shaping disease progression." This statement highlights a paradigm shift, suggesting that the microenvironment itself, rather than solely the mutated cells, plays a pivotal role in initiating and perpetuating the disease process.
Inflammation as an Early Driver of Blood Disease
The collective findings from this extensive research project strongly indicate that inflammation plays a central and early role in the pathogenesis of these blood disorders. Furthermore, the study unequivocally highlights the bone marrow microenvironment, often referred to as the bone marrow niche, as a prime therapeutic target. By shifting the focus from solely targeting the mutated stem cells themselves to understanding and modulating the ecosystem that supports these aberrant cells, the research opens up promising new avenues for early intervention and preventative strategies.
The implications for clinical practice are substantial. The development of anti-inflammatory drugs or novel therapies designed to precisely modulate interferon signaling could offer a means to preserve bone marrow function in older adults who have been diagnosed with CHIP. Moreover, combining these targeted anti-inflammatory approaches with existing therapies that act on the microenvironment holds the potential to significantly slow down or even prevent the progression from CHIP to more aggressive conditions like MDS or AML. The specific molecular signatures identified within iMSCs and interferon-responsive T cells also present a compelling opportunity to develop early diagnostic biomarkers, enabling the identification of individuals at elevated risk long before overt symptoms emerge.
"Our findings reveal that the bone marrow microenvironment actively shapes the earliest stages of malignant evolution," stated Guezguez, Principal Investigator in the Department of Hematology at UMC Mainz and co-senior author. "As advances in molecular profiling allow us to detect pre-leukemic states years before clinical onset, understanding how stromal and immune cells interact provides a foundation for preventive therapies that intercept disease progression before leukemia develops." This perspective emphasizes the potential for a proactive approach to blood cancer prevention, moving beyond traditional reactive treatment paradigms.
Inflammaging and the Wider Impact on Age-Related Disease
Beyond the direct implications for blood disorders, the results of this study contribute significantly to a broader understanding of ‘inflammaging.’ Inflammaging refers to the low-grade, chronic inflammation that is a hallmark of aging and is increasingly recognized as a contributing factor to a wide array of age-related conditions, including various forms of cancer, cardiovascular disease, and metabolic disorders. The bone marrow, long considered primarily a site of blood production, now appears to be both a victim of and a contributor to systemic inflammatory aging. By elucidating how the intricate interactions between immune cells and stromal cells drive these detrimental changes within the bone marrow, this study provides a robust model for investigating similar inflammatory remodeling processes in other myeloid malignancies and in the progression of advanced leukemia.
"It will be crucial to study these processes over time; our current findings are based on cross-sectional data," cautioned Zaugg. This acknowledgement of the study’s limitations is important. Future longitudinal studies will be essential to fully unravel the temporal dynamics of these changes. "This has important implications for therapies that replace malignant cells but leave the bone marrow niche intact, such as blood stem cell transplantation. We are now investigating to what extent the niche retains a ‘memory’ of disease, which could shape how it responds to new, healthy stem cells." This line of inquiry is critical for optimizing the success of cell-based therapies and understanding potential long-term outcomes.
The groundbreaking work presented in this study is further complemented by a parallel research effort, also published in the prestigious journal Nature Communications. This complementary study, led by Marc Raaijmakers from Erasmus MC Cancer Institute in Rotterdam, focuses on the MDS bone marrow microenvironment, offering a different but equally vital perspective. Together, these two independent yet interconnected studies provide a more holistic and comprehensive view of the inflammatory remodeling that occurs during the nascent phases of bone marrow diseases. This dual approach strengthens the scientific consensus and accelerates the translation of these discoveries into tangible clinical benefits.
The collaborative nature of this research underscores its significance, involving institutions such as UMC Mainz, University of Basel, University Hospital Dresden, Karolinska Institute Sweden, The Jackson Laboratory USA, and Sorbonne University, France, alongside partner institutions of the German Cancer Consortium (DKTK), including the German Cancer Research Center (DKFZ) and NCT Dresden. Funding for this extensive project was generously provided by the DKTK-CHOICE programme, an ERC grant awarded to Judith Zaugg (EpiNicheAML), the Marie Skłodowska-Curie Actions (MSCA)-funded ITN ENHPATHY, EMBO, the Swiss National Foundation, and the José Carreras Leukämie-Stiftung. This broad support network highlights the international commitment to advancing our understanding of blood cancers and age-related diseases.
